ALLIANCEBERNSTEIN L.P. - NGM BIOPHARMACEUTICALS INC ownership

NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 89 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 2.6%.

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of NGM BIOPHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$73,413
-61.3%
68,610
-6.4%
0.00%
Q2 2023$189,821
-25.9%
73,290
+16.7%
0.00%
Q1 2023$256,224
-14.2%
62,800
+5.5%
0.00%
Q4 2022$298,690
-40.9%
59,500
+54.1%
0.00%
Q3 2022$505,000
+2.0%
38,6000.0%0.00%
Q2 2022$495,000
+17.3%
38,600
+39.4%
0.00%
Q1 2022$422,000
-19.5%
27,700
-6.4%
0.00%
Q4 2021$524,000
-65.2%
29,600
-58.6%
0.00%
-100.0%
Q3 2021$1,505,000
+110.2%
71,576
+97.2%
0.00%
Q2 2021$716,000
-0.3%
36,300
+47.0%
0.00%
Q1 2021$718,000
-20.5%
24,700
-17.1%
0.00%
Q4 2020$903,000
+82.1%
29,800
-4.5%
0.00%
Q3 2020$496,000
-22.7%
31,200
-4.0%
0.00%
Q2 2020$642,000
+95.1%
32,500
+21.7%
0.00%
Q1 2020$329,000
+21.0%
26,700
+81.6%
0.00%
Q4 2019$272,000
+50.3%
14,700
+12.2%
0.00%
Q3 2019$181,00013,1000.00%
Other shareholders
NGM BIOPHARMACEUTICALS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Column Group LLC 15,396,116$303,611,00042.97%
Ponoi II Management, LLC 1,298,908$25,614,00020.76%
Ponoi Management, LLC 1,298,908$25,614,00014.23%
Euclidean Capital LLC 1,493,349$29,449,0009.56%
RHO CAPITAL PARTNERS INC 3,766,666$74,279,0006.80%
Aquilo Capital Management, LLC 1,194,237$23,550,0006.12%
Greenspring Associates, LLC 1,573,357$31,027,0002.10%
Octagon Capital Advisors LP 200,000$3,944,0000.82%
Redmile Group, LLC 2,792,448$55,067,0000.82%
BVF INC/IL 955,000$18,833,0000.71%
View complete list of NGM BIOPHARMACEUTICALS INC shareholders